Last reviewed · How we verify
Anti-OX40 Antibody PF-04518600 (anti-ox40-antibody-pf-04518600)
Anti-OX40 Antibody PF-04518600 (generic name: anti-ox40-antibody-pf-04518600) is a Monoclonal antibody Monoclonal antibody drug developed by Pfizer. It is currently FDA-approved for Non-small cell lung cancer, Hepatocellular carcinoma.
Anti-OX40 Antibody PF-04518600 is being studied in combination with Rituximab for Follicular Lymphoma, and in combination with other treatments for various types of cancer, including Recurrent Acute Myeloid Leukemia and Advanced Cancer. The mechanism of action of PF-04518600 is not specified in the provided information, but it is being investigated in a multi-cohort Phase 1b clinical trial.
At a glance
| Generic name | anti-ox40-antibody-pf-04518600 |
|---|---|
| Sponsor | Pfizer |
| Drug class | Monoclonal antibody |
| Target | OX40 receptor |
| Modality | Monoclonal antibody |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Approved indications
- Non-small cell lung cancer
- Hepatocellular carcinoma
Common side effects
Drug interactions
- Warfarin
- Aspirin
- P-glycoprotein inhibitors
- P-glycoprotein inducers
Key clinical trials
- Axitinib With or Without Anti-OX40 Antibody PF-04518600 in Treating Patients With Metastatic Kidney Cancer (PHASE2)
- Avelumab, Utomilumab, Anti-OX40 Antibody PF-04518600, and Radiation Therapy in Treating Patients With Advanced Malignancies (PHASE1, PHASE2)
- Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing (PHASE3)
- Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer (PHASE2)
- Rituximab + Immunotherapy in Follicular Lymphoma (PHASE1)
- A Study Of Avelumab In Combination With Other Cancer Immunotherapies In Advanced Malignancies (JAVELIN Medley) (PHASE1, PHASE2)
- OX40, Venetoclax, Avelumab, Glasdegib, Gemtuzumab Ozogamicin, and Azacitidine in Relapsed or Refractory Acute Myeloid Leukemia (PHASE1, PHASE2)
- Study Of OX40 Agonist PF-04518600 Alone And In Combination With 4-1BB Agonist PF-05082566 (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Anti-OX40 Antibody PF-04518600 CI brief — competitive landscape report
- Anti-OX40 Antibody PF-04518600 updates RSS · CI watch RSS
- Pfizer portfolio CI
Frequently asked questions about Anti-OX40 Antibody PF-04518600
What is Anti-OX40 Antibody PF-04518600?
What is Anti-OX40 Antibody PF-04518600 used for?
Who makes Anti-OX40 Antibody PF-04518600?
What is the generic name of Anti-OX40 Antibody PF-04518600?
What drug class is Anti-OX40 Antibody PF-04518600 in?
What development phase is Anti-OX40 Antibody PF-04518600 in?
What does Anti-OX40 Antibody PF-04518600 target?
Related
- Drug class: All Monoclonal antibody drugs
- Target: All drugs targeting OX40 receptor
- Manufacturer: Pfizer — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Non-small cell lung cancer
- Indication: Drugs for Hepatocellular carcinoma
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing